5:54 PM
 | 
Nov 08, 2013
 |  BC Extra  |  Company News

FDA committee to discuss dapagliflozin

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Dec. 12 to discuss a resubmitted NDA from Bristol-Myers Squibb...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >